Advances in  Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - August 2, 2019 Category: Dermatology Source Type: research

Ocular Co-Morbidities of Atopic Dermatitis. Part I: Associated Ocular Diseases
The objective of this article is to provide a current review of ocular diseases that commonly affect AD patients. The pathogenesis, clinical manifestations, diagnosis, and treatment of ocular co-morbidities of AD will be discussed. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - July 29, 2019 Category: Dermatology Source Type: research

Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma
ConclusionsDifferences between the authors ’ findings and official published ratings may be attributed to chronological issues, as many of the studies were not yet published when the aforementioned organizations conducted their reviews. There was also difficulty in applying the National Comprehensive Cancer Network criteria to this prognos tic test, as their guidelines were intended for evaluation of predictive markers. Nevertheless, based upon the most current data available, integration of the 31-GEP test into clinical practice may be warranted in certain clinical situations. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - July 29, 2019 Category: Dermatology Source Type: research

Ocular Co-Morbidities of Atopic Dermatitis. Part II: Ocular Disease Secondary to Treatments
The objective of this review is to raise awareness among dermatologists regarding the potential ocular adverse effects of various AD therapies, including corticosteroids, calcineurin inhibitors, an interleukin-4 receptor  α (IL-4Rα) antagonist, and phototherapy. Pertinent potential short- and long-term risks of these therapies include elevations in intraocular pressure from use of topical corticosteroids and conjunctivitis from use of dupilumab. Since some of these adverse effects may not exhibit symptomatology u ntil permanent vision impairment occurs, it is important for dermatologists to understand thes...
Source: American Journal of Clinical Dermatology - July 27, 2019 Category: Dermatology Source Type: research

The Treatment of Acne Scars, a 30-Year Journey
AbstractOver the past 30  years, the treatment of acne scars has undergone changes that have been significantly influenced by the concurrent development of new devices. The advent of fractional resurfacing lasers was a watershed moment for acne scarring therapy. The author recounts a career history of considerations of acn e scarring treatments as well as the literature supporting the experiences causing changes in practice. Fractional ablative and nonablative lasers, sublative radiofrequency, picosecond lasers, microneedling with and without radiofrequency and fillers are the bulk of the treatments covered, along wit...
Source: American Journal of Clinical Dermatology - July 20, 2019 Category: Dermatology Source Type: research

Oral Lesions in Autoimmune Bullous Diseases: An Overview of Clinical Characteristics and Diagnostic Algorithm
AbstractAutoimmune bullous diseases are a group of chronic inflammatory disorders caused by autoantibodies targeted against structural proteins of the desmosomal and hemidesmosomal plaques in the skin and mucosa, leading to intra-epithelial or subepithelial blistering. The oral mucosa is frequently affected in these diseases, in particular, in mucous membrane pemphigoid, pemphigus vulgaris, and paraneoplastic pemphigus. The clinical symptoms are heterogeneous and may present with erythema, blisters, erosions, and ulcers localized anywhere on the oral mucosa, and lead to severe complaints for the patients including pain, dy...
Source: American Journal of Clinical Dermatology - July 16, 2019 Category: Dermatology Source Type: research

Genital Psoriasis: Impact on Quality of Life and Treatment Options
AbstractPsoriasis involving the genital skin occurs in up to two-thirds of psoriasis patients but is often overlooked by physicians. Furthermore, psoriasis objective and subjective severity indexes for common plaque psoriasis often neglect the impact this small area of psoriasis can have on a patient. It can have a significant impact on patients ’ psychosocial function due to intrusive physical symptoms such as genital itch and pain, and a detrimental impact on sexual health and impaired relationships. The mainstay of treatment is topical therapy. In patients with genital psoriasis refractory to traditional topical t...
Source: American Journal of Clinical Dermatology - July 16, 2019 Category: Dermatology Source Type: research

Artificial Intelligence in Dermatology —Where We Are and the Way to the Future: A Review
This article aims to present a basic introduction to the concepts of artificial intelligence as well as  present an overview of the current research into artificial intelligence in dermatology, examining both its current applications and its future potential. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - July 5, 2019 Category: Dermatology Source Type: research

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
The objective of this study was to investigate the efficacy and safety of crisaborole according to patient race and ethnicity.MethodsA pooled post hoc analysis by race and ethnicity of the two pivotal trials and a safety extension trial was performed. Race included white or nonwhite (encompassing Asian/native Hawaiian/other Pacific Islander, black/African American, and other/American Indian/Alaskan native); ethnicity included Hispanic/Latino or not Hispanic/Latino.ResultsIn white, nonwhite, Hispanic/Latino, and not Hispanic/Latino groups at day 29, more crisaborole- than vehicle-treated patients achieved improvements in gl...
Source: American Journal of Clinical Dermatology - July 1, 2019 Category: Dermatology Source Type: research

Authors ’ Reply to Laneelle et al.: “Vascular Tests for Dermatologists”
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 25, 2019 Category: Dermatology Source Type: research

Comment on: Vascular Tests for Dermatologists
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 25, 2019 Category: Dermatology Source Type: research

Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council
ConclusionsThe PSI was useful for treated and untreated patients to enhance patient –physician communication, and influenced treatment decisions. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 21, 2019 Category: Dermatology Source Type: research

Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers
AbstractSkin cancer, as the most physically accessible malignancy, allows for the greatest variety in treatment innovation. The last 2 decades have seen striking increases in the life expectancies of those diagnosed with malignant melanoma. However, many cases remain in which disease prevails against standard treatment, and those patients rely on continuing ingenuity. Drugs that can be injected directly into patients ’ tumors have become increasingly promising, not least for the reduction in side effects observed. Intratumoral therapy encompasses a wide array of agents, from chemotherapeutic drugs to cancer vaccines....
Source: American Journal of Clinical Dermatology - June 21, 2019 Category: Dermatology Source Type: research

Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations
AbstractConsidered more efficacious and safer than traditional systemic drugs, biologic therapies have dramatically improved the quality of life of patients with psoriasis. Recently, there has been a proliferation of new targeted treatment options, including anti-interleukin-17, anti-interleukin-12/23, as well as small-molecule drugs such as apremilast. There are nevertheless some concerns regarding their use, especially in patients with chronic infections such as hepatitis B virus (HBV) and hepatitis C virus (HCV). It has been estimated that two billion individuals are infected with HBV worldwide and approximately 240 mil...
Source: American Journal of Clinical Dermatology - June 20, 2019 Category: Dermatology Source Type: research

Long-Term Effectiveness and Safety of Up to 48 Weeks ’ Treatment with Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in the Prevention and Reduction of Atrophic Acne Scars in Moderate and Severe Facial Acne
ConclusionsReductions in atrophic acne scars and acne lesions observed after 24  weeks of treatment with A0.3/BPO2.5 gel were maintained with treatment up to 48 weeks. The additional improvement in atrophic scar count with 48 weeks’ A0.3/BPO2.5 treatment, compared to delayed application at 24 weeks, highlights the importance of early initiation of effective acne treatment to prevent and reduce the formation of acne scars.Trial registrationClinicalTrials.gov identifier NCT02735421. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - June 17, 2019 Category: Dermatology Source Type: research

Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives
AbstractSurgical excision is the treatment of choice for early stage melanoma, and this strategy is initially curative for the vast majority of patients. However, only approximately 40 –60% of high-risk patients who undergo surgery alone will be disease-free at 5 years. These patients will ultimately experience loco-regional relapse or relapse at distant sites. The main aim of adjuvant therapies is to reduce the recurrence rate of radically operated patients at high risk and to potentially improve survival. Recent practice changing results with immune checkpoint inhibitors and targeted therapies have been publis...
Source: American Journal of Clinical Dermatology - June 8, 2019 Category: Dermatology Source Type: research

Biologic Treatment for Hidradenitis Suppurativa
AbstractPatients with hidradenitis suppurativa (HS) are often undertreated and there are limited efficacious therapies available for treating this population. Biologics are an emerging therapeutic modality used in the management of many inflammatory conditions including HS. Implementation of biologics is typically reserved for moderate-to-severe cases or in those cases that are refractory to treatment. Though many biologics have been trialed for use in HS, only one biologic, adalimumab, is currently US FDA (Food and Drug Administration) approved for the treatment of moderate-to-severe HS. Limitations in the use of biologic...
Source: American Journal of Clinical Dermatology - May 28, 2019 Category: Dermatology Source Type: research

Adult-Onset Atopic Dermatitis: Characteristics and Management
AbstractRecent epidemiological studies found the US prevalence of atopic dermatitis in adults to be approximately 7%. In particular, one in four adults with atopic dermatitis report adult onset of their disease. Adult-onset compared to child-onset atopic dermatitis is associated with distinct risk factors, lesional distribution and morphology, associated signs, genetics, and comorbidities. Adult-onset atopic dermatitis is a clinical diagnosis, and must be distinguished from other entities in the differential diagnosis, e.g., allergic contact dermatitis and cutaneous T-cell lymphoma. Further research is necessary to better ...
Source: American Journal of Clinical Dermatology - May 28, 2019 Category: Dermatology Source Type: research

Pediatric Laser Therapy in Pigmented Conditions
AbstractAdvances in laser therapy have led to novel therapeutic approaches to common pediatric skin conditions. As a non-invasive alternative to surgical options, laser therapy is efficacious in treating a broad range of conditions, from vascular and pigmented lesions to tattoo and hair removal. This paper reviews the basic mechanics of laser therapy, its role in common pigmented pediatric dermatoses, and special considerations for this unique age group. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 27, 2019 Category: Dermatology Source Type: research

Eruptive Melanocytic Nevi: A Review
AbstractEruptive melanocytic nevi (EMN) is a phenomenon characterized by the sudden onset of nevi. Our objective was to compile all published reports of EMN to identify possible precipitating factors and to evaluate the clinical appearance and course. We conducted a systematic bibliographic search and selected 93 articles, representing 179 patients with EMN. The suspected causes were skin and other diseases (50%); immunosuppressive agents, chemotherapy or melanotan (41%); and miscellaneous, including idiopathic (9%). The clinical manifestations could largely be divided into two categories: EMN associated with skin diseases...
Source: American Journal of Clinical Dermatology - May 22, 2019 Category: Dermatology Source Type: research

A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis
ConclusionsDaily long-term application of glycopyrronium tosylate for up to 48  weeks (double blind plus open label) was generally well tolerated and efficacy was maintained. No new safety signals emerged.Trial RegistryClinicaltrials.gov NCT02553798. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 20, 2019 Category: Dermatology Source Type: research

Onychomycosis in Athletes
AbstractOnychomycosis is a common disorder that is difficult to cure. Prevalence is lower in children (0.7%), but athletes are 2.5-fold more likely to develop the disease, with infections of the toenails seven times more prevalent than those of the fingernails. This is a concern for athletes as it can interfere with their performance. The risk of developing onychomycosis is increased by the warm environment of many sports activities; the use of occlusive footwear; the warm, moist environment associated with socks and sweating; shared, close quarters among athletes; and trauma to the foot and toenail. Once infected, onychom...
Source: American Journal of Clinical Dermatology - May 20, 2019 Category: Dermatology Source Type: research

Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data
ConclusionThe existing studies do not allow a robust evidence-based recommendation for the use of antiandrogens in the treatment of hidradenitis suppurativa/acne inversa. Further randomized controlled trials are needed to define the role of hormonal treatment as an alternative or concomitant therapy together with antibiotics or biologics. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 9, 2019 Category: Dermatology Source Type: research

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
AbstractBackgroundPatients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus kinase inhibitors) increase risk of infections. Dupilumab (a monoclonal antibody blocking the shared receptor component for IL-4 and IL-13) is approved for inadequately controlled moderate-to-severe AD and for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma.ObjectiveThe aim was to determine the impact of dupilumab on infection rates in patients w...
Source: American Journal of Clinical Dermatology - May 7, 2019 Category: Dermatology Source Type: research

Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens –Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database
ConclusionEarly systemic corticosteroid therapy for patients with SJS or TEN was not associated with lower in-hospital mortality. Further studies are needed to define the effect of corticosteroids for patients with SJS or TEN. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 30, 2019 Category: Dermatology Source Type: research

Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment
This article reviews the basic mechanisms of autoinflammation, followed by an update on the pathophysiology and treatment of the monogenic and multifactorial autoinflammato ry diseases, and the common dermatologic conditions in which autoinflammation plays a major role. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 17, 2019 Category: Dermatology Source Type: research

Special Considerations in the Treatment of Mycosis Fungoides
This article both highlights difficult clinical scenarios and reviews the recommended treatment as provided by the NCCN guidelines and provides alternative therapy for lesions that are either difficult to treat because of the location or are recalcitrant to the recommended therapy. With suggestions for the apparent gaps in guidelines, providers can better treat patients who present with more complicated conditions. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 16, 2019 Category: Dermatology Source Type: research

Vascular Tests for Dermatologists
This study reviews the most commonly ordered arterial and venous studies and discusses the appropriate indications and interpretation of these studies. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 15, 2019 Category: Dermatology Source Type: research

Quality-of-Life Research in Acne Vulgaris: Current Status and Future Directions
AbstractAcne patients may have significant quality-of-life (QoL) impairment, therefore assessment of health-related QoL (HRQoL) in acne patients is recommended by several national and international guidelines as an integral part of acne management. The inclusion of QoL assessment in core outcome sets is now a popular idea. Several acne-specific QoL questionnaires are available but none cover all topics presented in other instruments. The impact of acne on different aspects of QoL may vary between patients from different age groups. The European Academy of Dermatology and Venereology Task Force on Quality of Life and Patien...
Source: American Journal of Clinical Dermatology - April 4, 2019 Category: Dermatology Source Type: research

Psychological Therapies in Management of Psoriatic Skin Disease: A Systematic Review
ConclusionsBased on assigned levels of evidence, the most promising methods of psychological intervention in psoriasis include cognitive behavioral therapy, mindfulness-based therapies, motivational interviewing, and educational and interdisciplinary interventions. Further study is needed to determine the efficacy, practicality, and economic feasibility of these treatment options for patients with psoriasis. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 2, 2019 Category: Dermatology Source Type: research

Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis
The objective of the present study was to evaluate the effect of biological drugs on fatigue in patients with psoriasis vulgaris.MethodsWe conducted a meta-analysis of randomized controlled trials in which anti-interleukin-12/23, anti-interleukin-23, anti-interleukin-17, or anti-tumor necrosis factor- α agents were used for psoriasis vulgaris and fatigue was an outcome measure.ResultsA total of eight randomized controlled trials fulfilled criteria for inclusion in the meta-analysis. The studies used two fatigue reporting scales: the Functional Assessment of Chronic Illness Therapy-Fatigue and the Short Form 36 Health...
Source: American Journal of Clinical Dermatology - April 2, 2019 Category: Dermatology Source Type: research

Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis
AbstractTildrakizumab (tildrakizumab-asmn in the USA) [Ilumetri®; Ilumya ™] is a humanized monoclonal antibody (mAb) that selectively targets the p19 subunit of interleukin (IL)-23, thereby inhibiting the IL-23/IL-17 axis, the signalling pathway primarily implicated in the immunopathogenesis of psoriasis. Administered subcutaneously, it is approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy (e.g. in the EU and Australia) and those who are candidates for systemic therapy or phototherapy (in the USA). In the pivotal phase III reSURFACE 1 and 2 trials...
Source: American Journal of Clinical Dermatology - March 28, 2019 Category: Dermatology Source Type: research

Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review
ConclusionsSome patients develop active TB despite LTBI screening. Clinicians initiating biologic therapy in patients with psoriasis should be aware of the clinical features of active TB in this scenario. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 27, 2019 Category: Dermatology Source Type: research

Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis
AbstractAs the first targeted systemic agent for the treatment of moderate to severe atopic dermatitis (AD), dupilumab represents a novel therapeutic opportunity for both patients and providers. However, a subset of patients receiving dupilumab are either partial responders who exhibit some improvement in Investigator ’s Global Assessment score but not sufficient to meet the primary endpoint, or are non-durable responders who achieve therapeutic endpoint with subsequent partial loss of efficacy. We propose a therapeutic algorithm for the management of dupilumab partial responders and non-durable responders that invol...
Source: American Journal of Clinical Dermatology - March 27, 2019 Category: Dermatology Source Type: research

Childhood Vitiligo
AbstractVitiligo is a common acquired depigmenting skin disease characterized by a progressive loss of functional melanocytes. It may appear from the first years of life to late adulthood. Childhood vitiligo (CV), defined as vitiligo that begins before the age of 12  years, is common and may differ from post-CV in terms of epidemiology, clinical presentation, comorbidities, and treatment options. Taking into consideration the potential significant psychosocial impact of the disease on both children and their parents, all available therapeutic options must be o ffered to patients who desire treatment. According to the ...
Source: American Journal of Clinical Dermatology - March 25, 2019 Category: Dermatology Source Type: research

Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review
AbstractSarcoidosis is an inflammatory disease defined by the presence of non-caseating granulomas. It can affect a number of organ systems, most commonly the lungs, lymph nodes, and skin. Cutaneous manifestations of sarcoidosis can impose a significant detriment to patients ’ quality of life. The accepted first-line therapy for cutaneous sarcoidosis consists of intralesional and oral corticosteroids, but these can fail in the face of resistant disease and corticosteroid-induced adverse effects. Second-line agents include tetracyclines, hydroxychloroquine, and methotr exate. Biologics are an emerging treatment option...
Source: American Journal of Clinical Dermatology - March 20, 2019 Category: Dermatology Source Type: research

American Academy of Dermatology Annual Meeting: Washington, DC, USA, 1 –5 March 2019
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - March 19, 2019 Category: Dermatology Source Type: research

Chronic Cutaneous Lupus Erythematosus: Depression Burden and Associated Factors
ConclusionOver one-quarter of a predominantly Black population-based cohort of individuals with primary CCLE reported moderate to severe depression, a rate three to five times higher than described previously in the general population from the same metropolitan Atlanta area. Our findings suggest that, while patient ’s perception of discrimination in the healthcare setting may play a role as a determinant of depression, social support may be protective. In addition to routine mental health screening and depression treatment, interventions directed at providing emotional support and improving office staff inte rpersona...
Source: American Journal of Clinical Dermatology - March 15, 2019 Category: Dermatology Source Type: research

HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management
AbstractAntiretroviral therapy (ART) has revolutionized the treatment and prognosis of people living with HIV (PLHIV). With increased survival and improved overall health, PLHIV are experiencing dermatologic issues both specific to HIV and common to the general population. In this new era of ART, it is crucial for dermatologists to have a strong understanding of the broad range of cutaneous disease and treatment options in this unique population. In this review, we outline the most common skin diseases in PLHIV, including HIV-associated malignancies, inflammatory conditions, and infections, and focus on the role of ART in ...
Source: American Journal of Clinical Dermatology - February 26, 2019 Category: Dermatology Source Type: research

Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma
AbstractMerkel cell carcinoma (MCC) is an aggressive skin cancer. Until 2017, patients with advanced disease were typically treated with conventional chemotherapies, with a median response duration of 3  months. Increased evidence of the role of the immune system in controlling this cancer has paved the way for immune-based therapies, with programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitors at the frontline. Avelumab, an anti-PD-L1 antibody, was the f irst-ever drug approved in advanced MCC after showing meaningful efficacy in a second-line setting. Objective resp...
Source: American Journal of Clinical Dermatology - February 19, 2019 Category: Dermatology Source Type: research

Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma
AbstractCutaneous squamous cell carcinoma (CSCC) is one of the most common human malignancies, and the incidence is increasing with time. High mutational loads, known infiltration with lymphocytes, and programmed death (PD)-ligand 1 (PD-L1) expression suggest that immune checkpoint inhibitors, such  as PD-1 inhibitors, may show utility in treating CSCC, similar to response see in other solid tumor types. Recently, the robust responsiveness of CSCCs to the PD-1 inhibitor cemiplimab was revealed in the results of a combined phase I/II clinical trial, with an overall response rate of 50% and a d urable response exceeding...
Source: American Journal of Clinical Dermatology - February 8, 2019 Category: Dermatology Source Type: research

KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development
AbstractMetastatic melanoma is a heterogenous disease that has served as a model for the development of both targeted therapy and immunotherapy. KIT-mutated melanoma represents a rare subset, most commonly arising from acral, mucosal, and chronically sun-damaged skin. Additionally, KIT alterations are enriched in the triple wild-type subtype of cutaneous melanoma. Activating alterations of KIT —a transmembrane receptor tyrosine kinase important for cell development, growth, and differentiation—have been shown to be critical to oncogenesis across many tumor subtypes. Following the successes of BRAF-targeted ther...
Source: American Journal of Clinical Dermatology - February 1, 2019 Category: Dermatology Source Type: research

Trends in Utilization and Expenditure for Onychomycosis Treatments in the United States in 2013 –2016
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - January 31, 2019 Category: Dermatology Source Type: research

Topical Retinoids in Acne Vulgaris: A Systematic Review
AbstractBackgroundTopical retinoids are a first-line treatment for acne vulgaris.ObjectiveThis systematic review aims to evaluate the efficacy, safety, and tolerability of topical retinoids approved in the United States for the treatment of acne vulgaris.MethodsA PubMed and Embase search was conducted using the search terms ‘adapalene,’ ‘tretinoin,’ ‘tazarotene,’ and ‘acne vulgaris.’ Selection of articles fit the following inclusion criteria: clinical trials evaluating both efficacy and safety/tolerability of topical retinoids approved in the United States for the treatment o...
Source: American Journal of Clinical Dermatology - January 23, 2019 Category: Dermatology Source Type: research

Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment
AbstractFrontal fibrosing alopecia (FFA), first described by Kossard in the early 1990s, is a form of primary lymphocytic cicatricial alopecia characterized  by selective involvement of the frontotemporal hairline and eyebrows. Since the original description, an increasing number of cases have been reported worldwide and the clinical aspects of the disease have been better characterized. However, the pathogenesis is still unknown and several hypotheses have been made about possible triggering factors, including hormones, neurogenic inflammation, smoking, UV filters, and ingredients in leave-on facial products. A genet...
Source: American Journal of Clinical Dermatology - January 19, 2019 Category: Dermatology Source Type: research

Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come?
We present a comprehensive review of the literature on DReSS/DiHS, focusing on its history, etiopathogenesis, diagnosis, therapeutic approach, and outcome. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - January 17, 2019 Category: Dermatology Source Type: research

Association Between Psoriasis and Dementia: A Population-Based Case –Control Study
This study used a population-based medical dataset to explore the association between previously diagnosed psoriasis and dementia in Taiwan.MethodsUsing the Taiwan Longitudinal Health Insurance Database 2000, we identified 7118 individuals with a diagnosis of dementia; a further 21,354 sex- and aged-matched individuals were randomly extracted as controls. Patients with bullous pemphigoid, which is characterized by inflammatory phenomena similar to that evident in psoriasis, were chosen as a control group. Conditional logistic regression was performed to evaluate the association between dementia and prior psoriasis or bullo...
Source: American Journal of Clinical Dermatology - January 16, 2019 Category: Dermatology Source Type: research

Acne, the Skin Microbiome, and Antibiotic Treatment
AbstractAcne vulgaris is a chronic skin disorder involving hair follicles and sebaceous glands. Multiple factors contribute to the disease, including skin microbes. The skin microbiome in the follicle is composed of a diverse group of microorganisms. Among them,Propionibacterium acnes andMalassezia spp. have been linked to acne development through their influence on sebum secretion, comedone formation, and inflammatory response. Antibiotics targetingP. acnes have been the mainstay in acne treatment for the past four decades. Among them, macrolides, clindamycin, and tetracyclines are the most widely prescribed. As anti...
Source: American Journal of Clinical Dermatology - January 10, 2019 Category: Dermatology Source Type: research

Neutrophilic Dermatoses Associated with Myeloid Malignancies
AbstractNeutrophilic dermatoses (ND) are a group of conditions characterized by an aseptic accumulation of polymorphonuclear leukocytes in the skin. Occurrence of ND in association with myeloid malignancies, mainly myelodysplastic syndrome and myelogenous acute leukemia, is not rare and is often associated with a poor prognosis. Recent findings have improved understanding of the pathophysiology of myeloid malignancy-associated ND. We review the clinical spectrum of myeloid malignancy-associated ND with an emphasis on recently identified mechanisms. Myeloid leukemia cells retain the potential for terminal differentiation in...
Source: American Journal of Clinical Dermatology - January 10, 2019 Category: Dermatology Source Type: research

Correction to: JAK Inhibitors for Atopic Dermatitis: An Update
Page 7, Table  1, ASN002 row. The cell entry in column 4, “Manufacturer”, which previously read: (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - January 10, 2019 Category: Dermatology Source Type: research